EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry

Marnix Lam iD, David Kersting, William Harris, Eveline Boucher, Etienne Garin, Kirk Fowers, Riad Salem

European Journal of Nuclear Medicine and Molecular Imaging · 2026-08 · 53 (10) · 5994-5998

DOI: 10.1007/s00259-026-07948-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 29.05.2026. Verfasst von Marnix Lam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, P.O. Box 85500, Utrecht, 3508 GA, The Netherlands. m.lam@umcutrecht.…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Liver Neoplasms, Radioembolization, Therapeutic. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

EPOCH demonstrated superior progression free survival using yttrium-90 [ 90 Y] glass microspheres radioembolization plus chemotherapy versus chemotherapy in colorectal cancer patients with liver metastases who had progressed following first-line oxaliplatin or irinotecan-based chemotherapy. Exploratory post-hoc analyses and theoretical modeling assessed the potential impact of dosimetry on safety outcomes. Patients and methods Liver-related treatment-emergent adverse event (TEAE) frequency and/or severity, and bilirubin increase were explored in participating patients. For hypothesis generation, a theoretical model was constructed to understand EPOCH dosimetry in the absence of multicompartment dosimetry data.

Results

Liver-related TEAEs were reported in 93/186 (50%) patients, TEAEs ≥ grade 3 in 44/186 (24%) patients. A total of 26/186 patients (14%) experienced a bilirubin increase TEAE of any grade, in five of which assessed as related to glass [ 90 Y]Y-radioembolization with a median fractional tumour involvement of 2.3% (range 1.4–4.1%). Under the theoretical assumption of a T/N ratio of 2–10, most patients in EPOCH (62% had a fractional tumour involvement < 10%) received a normal liver absorbed dose of at least 75 Gy. In this model, at < 4.1% fractional tumour involvement, the normal liver absorbed dose approximates 120 Gy at any T/N ratio.

Conclusion

When treatment is same-day whole liver at 120 Gy average absorbed dose, the normal liver absorbed dose is dependent on fractional tumour involvement. Trial Registration ClinicalTrials.gov NCT01483027.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsLiver NeoplasmsRadioembolization, TherapeuticAgedFemaleHumansMaleMiddle AgedMicrospheresRadiometryYttrium Radioisotopes

Stichwörter der Autor:innen

Colorectal carcinomaDosimetryLiverRadioembolizationYttrium

Substanzen

Yttrium RadioisotopesYttrium-90

Autor:innen und Institutionen

  • Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, P.O. Box 85500, Utrecht, 3508 GA, The Netherlands. m.lam@umcutrecht.nl.
  • Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
  • Division of Hematology and Oncology, University of Washington, Seattle, WA, USA.
  • Boston Scientific Corporation, Marlborough, MA, USA.
  • Department of Nuclear Medicine, Cancer Institute Eugene Marquis, Rennes, France.
  • Department of Radiology, Northwestern University, Chicago, IL, USA.

ORCID-Profile: Marnix Lam

Zitieren

APA

Lam, M., Kersting, D., Harris, W., Boucher, E., Garin, E., Fowers, K., & Salem, R. (2026). Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 53(10), 5994-5998. https://doi.org/10.1007/s00259-026-07948-6

Vancouver

Lam M, Kersting D, Harris W, Boucher E, Garin E, Fowers K, et al. Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(10):5994-5998. doi:10.1007/s00259-026-07948-6

BibTeX
@article{Lam2026,
  author = {Lam, Marnix and Kersting, David and Harris, William and Boucher, Eveline and Garin, Etienne and Fowers, Kirk and Salem, Riad},
  title = {Post-hoc analysis of adverse events during the EPOCH trial: reconsidering dosimetry},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {10},
  pages = {5994--5998},
  doi = {10.1007/s00259-026-07948-6}
}
Kostenlos starten →